Insulin lispro

In plain language

Insulin lispro is a lab-modified version of human insulin that works faster, so people can inject it right before a meal instead of waiting 30 minutes. It is sold as Humalog and as follow-on products.

Researchers swapped two amino acids at one end of the molecule so the insulin molecules stop sticking together in clumps under the skin. That lets it get into the blood quickly, act strongly during the meal, and wear off soon after.

For students

Insulin lispro is human insulin with proline and lysine swapped at B28 and B29 (LysB28-ProB29), about 5,808 Da. The swap disrupts self-association into dimers and hexamers, so the injected depot absorbs rapidly (onset ~15 minutes, peak ~1-2 hours, duration 3-5 hours) without changing receptor binding affinity.

It is used as prandial insulin in both type 1 and type 2 diabetes, often paired with basal analogues. Its development in the early 1990s was the first demonstration that modifying insulin's self-assembly, not its receptor interaction, could tune pharmacokinetics, a principle that underlies all modern insulin analogue design.

For researchers and instructors

Biochemistry. The B-chain C-terminal swap targets the dimer interface; hydrophobic side chains critical for hexamer formation remain available for receptor binding, which is why potency is preserved.

Pharmacology. Absorption is faster and less variable than regular insulin; the shorter duration reduces late postprandial hypoglycemia, and it can be injected within 15 minutes of eating or immediately after.

Human evidence. Multiple crossover trials showed reduced postprandial glucose excursions and less nocturnal hypoglycemia versus regular insulin; long-term safety is comparable to human insulin.

Teaching point. A classic example of rational drug design solving a biophysical problem (self-association) rather than a receptor problem.